|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Report calls for new revolution in contraceptive technology. |
| POPULATION TODAY. 1996 Sep;24(9):1-2. |
| In response to the high rates of contraceptive failure and abortion in the US, members of an Institute of Medicine |
| (National Academy of Sciences) panel called for a "second contraceptive revolution." Since oral contraceptives were |
| introduced in the early 1960s, social, legal, and financial barriers have stalled any further development of new |
| methods. Most research activity has focused on modifying existing hormonal methods rather than creating new |
| technology. Essential is stronger collaboration between government, industry, private insurers, and the public. |
| Product liability concerns have been a major obstacle, in the US more than in other countries. Thus, the panel |
| called for a statute that would protect manufacturers from certain lawsuits if their contraceptives had been approved |
| by the US Food and Drug Administration. Given the pharmaceutical industry's insistence on clearer drug regulatory |
| protocol as a condition of contraceptive development, the panel recommended immediate guidelines for high-priority |
| areas such as spermicides and vaginal microbicides. To spread the legal and financial risks associated with the |
| development of anti- and post-implantation methods such as RU-486, the panel urged that small biotech firms form |
| partnerships with nonprofit organizations and large pharmaceutical companies. Another option for new contraceptive |
| development is a global contraceptive commodity program or multilateral purchasing pool, in which competing |
| manufacturers would be eligible for volume purchases of their products by the sponsoring agencies. (PubHealth.info |
| Document ID: CONT2T 2060-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Report calls for new revolution in contraceptive |
| technology.", is(are) Durbin S. The source of this article is "POPULATION TODAY. 1996 Sep;24(9):1-2.". This |
| article was published in 1996 in English language(s). (PubHealth.info® Document ID: CONT2T 2060-06. All rights |
| reserved with PubHealth.info) PIN: 7060 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
